ArticleHIV/AIDS (Auckland, N.Z.)2025
Spectrum and Correlates of Dyslipidemia in People Living with HIV on Dolutegravir-Based Regimen Attending Kabutare Hospital, Southern Rwanda: A Cross-Sectional Study.
Article in HIV/AIDS (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Prevalence and Correlates of Dyslipidemia in HIV-Positive Patients at Selected Public Hospitals in Addis Ababa, Ethiopia, 2025.AIDS research and treatment · 2026Article
- Article
- High dyslipidemia in people living with HIV in ghana: a cross-sectional analysis of prevalence and associated factors.AIDS research and therapy · 2025Article
- Association Between High Serum Alanine Aminotransferase to High Density Lipoprotein Cholesterol Ratio and Metabolic Syndrome among People Living with HIV on Dolutegravir-Based ART in South-Western Uganda.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dyslipidemia, a risk factor for cardiovascular disease (CVD), is common among people living with the human immunodeficiency virus (HIV). The interaction between HIV, dolutegravir (DTG)- based antiretroviral therapy (ART), and lifestyle factors contribute to dyslipidemia, increasing CVD risk. Rwanda has made significant progress in expanding access to ART, achieving high coverage and viral suppression rates. However, comprehensive data on dyslipidemia among people living with HIV (PLWH) in Rwanda is lacking. Therefore, this study aimed to fill this gap by examining the prevalence, types, and correlates of dyslipidemia among PLWH. Methods: This cross-sectional study with 264 participants analyzed serum lipid profiles to estimate the prevalence of dyslipidemia and specific lipid abnormalities. Demographic and lifestyle factors were collected using a questionnaire. Differences in categorical variables between HIV-positive and HIV-negative groups were assessed using chi-square or Fisher's exact tests. Continuous variables were compared using the Wilcoxon rank-sum test. Multivariable logistic regression models, stratified by HIV status, identified factors independently associated with dyslipidemia, reported as adjusted odds ratios (aOR) and 95% confidence intervals (CI). Statistical significance was defined as p-value < 0.05. Results: Dyslipidemia (NCEP ATP III criteria) was present in 74.2% of participants, significantly higher among PLWH (82.7%) than HIV-negative group (59.4%). Hypoalphalipoproteinemia and hyperbetalipoproteinemia were more common in PLWH (72.6% and 53.0%) vs HIV-negative (57.3% and 3.1%). Male gender reduced odds of dyslipidemia in both groups; smoking significantly increased risk among PLWH (aOR 8.8; 95% CI 1.73-44.59), while alcohol consumption was protective (aOR 0.2; 95% CI 0.07-0.55). DTG- based ART duration > 6-12 months increased odds of dyslipidemia vs ≤ 6 months (aOR 4.8; 95% CI 1.11-20.93). Conclusion: The study found a high prevalence of dyslipidemia among PLWH on ART, linked to ART duration, age, smoking and sex, highlighting the need for regular screening, lifestyle interventions, and tailored HIV care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.